X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abridged index medicus (2) 2
adult (2) 2
body mass index (2) 2
body weight loss (2) 2
clinical trials (2) 2
diabetes mellitus (2) 2
double-blind method (2) 2
evidence-based medicine (2) 2
exercise (2) 2
female (2) 2
food and nutrition (2) 2
glucagon-like peptide 1 - analogs & derivatives (2) 2
human health and pathology (2) 2
humans (2) 2
index medicus (2) 2
injections, subcutaneous (2) 2
life sciences (2) 2
male (2) 2
medicine, general & internal (2) 2
middle aged (2) 2
obesity (2) 2
obesity - drug therapy (2) 2
risk factors (2) 2
weight control (2) 2
weight loss - drug effects (2) 2
3.0 mg (1) 1
adult; blood glucose; body mass index; combined modality therapy; counseling; diarrhea; diet, reducing; double-blind method; exercise; female; glucagon-like peptide 1; humans; hypoglycemic agents; injections, subcutaneous; liraglutide; male; middle aged; nausea; obesity; weight loss; medicine (1) 1
analysis (1) 1
autoimmune diseases (1) 1
back pain (1) 1
blood glucose - analysis (1) 1
blood glucose - drug effects (1) 1
blood glucose - metabolism (1) 1
body weight (1) 1
body weight - drug effects (1) 1
cardiac arrest (1) 1
classification (1) 1
clinical medicine (1) 1
combined modality therapy (1) 1
counseling (1) 1
diabetes (1) 1
diabetes mellitus, type 2 - diagnosis (1) 1
diabetes mellitus, type 2 - drug therapy (1) 1
diabetes therapy (1) 1
diagnosis (1) 1
diarrhea (1) 1
diarrhea - chemically induced (1) 1
diet, reducing (1) 1
dosage and administration (1) 1
drug therapy (1) 1
dyslipidemia (1) 1
evaluation (1) 1
exenatide (1) 1
gallbladder diseases (1) 1
gastrointestinal surgery (1) 1
glucagon (1) 1
glucagon-like peptide 1 (1) 1
glucagon-like peptide 1 - administration & dosage (1) 1
glucagon-like peptide 1 - adverse effects (1) 1
glucagon-like peptide 1 - pharmacology (1) 1
glucagon-like peptide-1 receptor - administration & dosage (1) 1
glucagon-like peptide-1 receptor - agonists (1) 1
glucose (1) 1
glucose metabolism (1) 1
health aspects (1) 1
health risks (1) 1
hemoglobin (1) 1
hypertension (1) 1
hypoglycemic agents - administration & dosage (1) 1
hypoglycemic agents - adverse effects (1) 1
hypoglycemic agents - therapeutic use (1) 1
immunology (1) 1
incretins - therapeutic use (1) 1
internal medicine (1) 1
investigations (1) 1
life-style (1) 1
life-style intervention (1) 1
liraglutide (1) 1
liraglutide - administration & dosage (1) 1
liraglutide - adverse effects (1) 1
liraglutide - pharmacology (1) 1
maintenance (1) 1
medicine (1) 1
metabolism (1) 1
nausea (1) 1
nausea - chemically induced (1) 1
normal glucose regulation (1) 1
nutrition research (1) 1
obese subjects (1) 1
obesity - complications (1) 1
obesity - epidemiology (1) 1
obesity - therapy (1) 1
overweight (1) 1
overweight persons (1) 1
parameters (1) 1
physical activity (1) 1
placebo effect (1) 1
placebos - administration & dosage (1) 1
placebos - pharmacology (1) 1
prediabetic state (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by le Roux, Carel W and Astrup, Arne and Fujioka, Ken and Greenway, Frank and Lau, David C W and Van Gaal, Luc and Ortiz, Rafael Violante and Wilding, John P H and Skjøth, Trine V and Manning, Linda Shapiro and Pi-Sunyer, Xavier and Hamann, Andreas and Barakat, Alain and Blüher, Matthias and Linn, Thomas and Mölle, Andrea and Segner, Alexander and Stübler, Petra and Tosch-Sisting, Regina and Pacini, Furio and Santini, Ferruccio and Marchesini, Giulio and Rotella, Carlo Maria and Invitti, Cecilia and Vettor, Roberto and Buscemi, Silvio and Raya, Pedro Mezquita and Freijoo, Felipe Casanueva and de Barbará, Ramón Gomis and Carraro, Raffaele and Bobillo, Enrique Romero and de la Cuesta, Carmen and Farsang, Csaba and Csaszar, Albert and Zahorska-Markiewicz, Barbara and Pupek-Musialik, Danuta and Franek, Edward and Ostrowska, Lucyna and Olszanecka-Glinianowicz, Magdalena and Lalic, Nebojsa and Micic, Dragan and Ludvik, Bernhard and Paulweber, Bernhard and Prager, Rudolf and Scheen, André and Astrup, Arne Vernon and Hermansen, Kjeld and Madsbad, Sten and Rissanen, Aila and Nieminen, Sakari and Savolainen, Markku and Krempf, Michel and Romon, Monique and Laville, Martine and Marre, Michel and Mira, Reginald and Finucane, Francis and Veenendaal, Aletha and van Berkum, Frank and Johannsson-Vidarsdóttir, Solrun and Van de Walle, Vivienne and Meesters, Eelco and Hjelmesæth, Jøran and Klemsdal, Tor Ole and Kulseng, Bård and Bach-Kliegel, Birgit and Laederach, Kurt and Villiger, Lukas and Golay, Alain and Bilz, Stefan and Sathyapalan, Thozhukat and Bain, Stephen and Kumar, Sudesh and Le Roux, Carel Wynard and Lean, Michael E.J and McGowan, Barbara and Rehman, Tariq and Wilding, John and Wittert, Gary and Caterson, Ian and Proietto, Joeseph and Prins, John and Neto, Bruno Geloneze and Gross, Jorge Luiz and Chacra, Antonio Roberto and Halpern, Alfredo and de Almeida Suplicy, Henrique and Chow, Francis Chun Chung and Thacker, Hemant P and Chadha, Manoj and Chandalia, Hemaraj and Unnikrishnan, Ambika and Kalra, Sanjay and Deshpande, Neeta and Shunmugavelu, Minakshi and Deshmukh, Vaishali Chetan and Maislos, Maximo and Lieberman, Gabriella Segal and Shimon, Ilan and Stern, Naftali and ... and SCALE Obesity Prediabetes NN8022-1839 Study Group and SCALE Obesity & Prediabet NN8022
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10077, pp. 1399 - 1409
Summary Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials... 
Internal Medicine | 3.0 MG | REGRESSION | MEDICINE, GENERAL & INTERNAL | OBESE SUBJECTS | LIFE-STYLE | EXENATIDE | PREVENTION | NORMAL GLUCOSE REGULATION | Obesity - drug therapy | Glucagon-Like Peptide-1 Receptor - administration & dosage | Humans | Middle Aged | Body Weight - drug effects | Male | Weight Loss - drug effects | Liraglutide - pharmacology | Injections, Subcutaneous | Adult | Female | Placebos - administration & dosage | Body Mass Index | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Risk Reduction Behavior | Glucagon-Like Peptide 1 - analogs & derivatives | Obesity - complications | Glucagon-Like Peptide 1 - pharmacology | Prediabetic State - prevention & control | Treatment Outcome | Prediabetic State - complications | Blood Glucose - drug effects | Prediabetic State - diagnosis | Diabetes Mellitus, Type 2 - diagnosis | Liraglutide - adverse effects | Obesity - epidemiology | Placebos - pharmacology | Incretins - therapeutic use | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Clinical trials | Glucose metabolism | Risk factors | Prediabetic state | Diabetes therapy | Exercise | Obesity | Evaluation | Diabetes mellitus | Health risks | Weight loss | Glucose | Evidence-based medicine | Placebo effect | Studies | Weight control | Randomization | Immunology | Classification | Weight reduction | Gastrointestinal surgery | Diabetes | Clinical medicine | Diagnosis | Autoimmune diseases | Risk management | Back pain | Physical activity | Gallbladder diseases | Body weight loss | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Hypertension | Risk reduction | Metabolism | Investigations | Nutrition research
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 1, pp. 11 - 22
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.